巨核细胞在骨髓纤维化中的作用。
The Role of Megakaryocytes in Myelofibrosis.
机构信息
Division of Experimental Hematology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MC341, Memphis, TN 38105, USA. Electronic address: https://twitter.com/melo_cardenas1.
Department of Biomedical and Neuromotor Sciences, University of Bologna, Via Irnerio, 48 - I 40126, Bologna, Italy.
出版信息
Hematol Oncol Clin North Am. 2021 Apr;35(2):191-203. doi: 10.1016/j.hoc.2020.11.004. Epub 2021 Jan 11.
Abstract
Megakaryocytes give rise to platelets, which have a wide variety of functions in coagulation, immune response, inflammation, and tissue repair. Dysregulation of megakaryocytes is a key feature of in the myeloproliferative neoplasms, especially myelofibrosis. Megakaryocytes are among the main drivers of myelofibrosis by promoting myeloproliferation and bone marrow fibrosis. In vivo targeting of megakaryocytes by genetic and pharmacologic approaches ameliorates the disease, underscoring the important role of megakaryocytes in myeloproliferative neoplasms. Here we review the current knowledge of the function of megakaryocytes in the JAK2, CALR, and MPL-mutant myeloproliferative neoplasms.
摘要
巨核细胞生成血小板，血小板在凝血、免疫反应、炎症和组织修复中具有多种功能。巨核细胞的失调是骨髓增生性肿瘤的一个关键特征，尤其是骨髓纤维化。巨核细胞通过促进骨髓增生和骨髓纤维化成为骨髓纤维化的主要驱动因素之一。通过遗传和药理学方法在体内靶向巨核细胞可改善疾病，这突显了巨核细胞在骨髓增生性肿瘤中的重要作用。在这里，我们回顾了巨核细胞在 JAK2、CALR 和 MPL 突变型骨髓增生性肿瘤中的功能的现有知识。
相似文献
1
The Role of Megakaryocytes in Myelofibrosis.巨核细胞在骨髓纤维化中的作用。
Hematol Oncol Clin North Am. 2021 Apr;35(2):191-203. doi: 10.1016/j.hoc.2020.11.004. Epub 2021 Jan 11.
2
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.四种不同亚型骨髓增殖性肿瘤患者（原发性骨髓纤维化、原发性血小板增多症、真性红细胞增多症和无法分类的骨髓增殖性肿瘤）的CALR、JAK2和MPL突变谱
Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM.
3
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.骨髓增殖性疾病诊断标准的概念变迁以及骨髓增殖性肿瘤的分子病因学与分类：从1950年的达梅谢克到2005年的万琴克尔及以后
Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7.
4
MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.MPL 过表达诱导高水平的突变-CALR/MPL 复合物：CALR 突变的骨髓增殖性肿瘤中鲁索替尼耐药的新机制。
Int J Hematol. 2021 Oct;114(4):424-440. doi: 10.1007/s12185-021-03180-0. Epub 2021 Jun 24.
5
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.从 Janus 激酶 2 到钙网蛋白：骨髓增殖性肿瘤的临床相关基因组图谱。
Blood. 2014 Jun 12;123(24):3714-9. doi: 10.1182/blood-2014-03-530865. Epub 2014 Apr 30.
6
Essential thrombocythaemia with mutation in : clinicopathological correlation and comparison with 2V617F-mutated and mutated genotypes.伴有 JAK2 V617F 突变的原发性血小板增多症：临床病理相关性及与 JAK2 V617F 突变和突变基因型的比较
J Clin Pathol. 2018 Nov;71(11):975-980. doi: 10.1136/jclinpath-2018-205227. Epub 2018 Jun 22.
7
[Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].[钙网蛋白基因突变与JAK2/MPL阴性骨髓增殖性肿瘤的关系]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Oct;23(5):1532-4. doi: 10.7534/j.issn.1009-2137.2015.05.060.
8
Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.印度BCR-ABL1阴性骨髓增殖性肿瘤的分子遗传学
Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):209-213. doi: 10.4103/IJPM.IJPM_223_17.
9
Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
10
[Clinical application of gene mutation information in myeloproliferative neoplasms].基因突变信息在骨髓增殖性肿瘤中的临床应用
Rinsho Ketsueki. 2019;60(6):610-618. doi: 10.11406/rinketsu.60.610.
引用本文的文献
1
Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations.明显骨髓纤维化患者的极端血小板增多症及其临床关联
Cancers (Basel). 2025 Apr 22;17(9):1390. doi: 10.3390/cancers17091390.
2
Warm Autoimmune Hemolytic Anemia as a Rare Presentation of Pre-fibrotic Primary Myelofibrosis.温抗体型自身免疫性溶血性贫血作为纤维化前期原发性骨髓纤维化的罕见表现。
Cureus. 2024 Dec 5;16(12):e75155. doi: 10.7759/cureus.75155. eCollection 2024 Dec.
3
Versatility of megakaryocytes in homeostasis and disease.巨核细胞在体内平衡和疾病中的多功能性。
Blood Sci. 2024 Nov 28;6(4):e00212. doi: 10.1097/BS9.0000000000000212. eCollection 2024 Oct.
4
Daratumumab improved severe neutrophilia and paraneoplastic bone marrow fibrosis in granulocyte-colony stimulating factor-producing multiple myeloma.达雷妥尤单抗改善了粒细胞集落刺激因子分泌型多发性骨髓瘤中的严重中性粒细胞增多症和副肿瘤性骨髓纤维化。
EJHaem. 2024 May 8;5(3):638-641. doi: 10.1002/jha2.901. eCollection 2024 Jun.
5
CCN2/CTGF expression does not correlate with fibrosis in myeloproliferative neoplasms, consistent with noncanonical TGF-β signaling driving myelofibrosis.CCN2/CTGF 表达与骨髓增殖性肿瘤中的纤维化无关，与非经典 TGF-β 信号传导驱动骨髓纤维化一致。
Virchows Arch. 2024 May;484(5):837-845. doi: 10.1007/s00428-024-03799-4. Epub 2024 Apr 11.
6
CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis.原发性骨髓纤维化中的 CXCL8 及其同源受体 CXCR1/CXCR2。
Haematologica. 2024 Jul 1;109(7):2060-2072. doi: 10.3324/haematol.2023.284921.
7
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.骨髓纤维化患者接受莫洛替尼或芦可替尼治疗期间，骨髓纤维化的变化与疗效结果无关。
EJHaem. 2024 Feb 5;5(1):105-116. doi: 10.1002/jha2.854. eCollection 2024 Feb.
8
Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.骨髓增殖性肿瘤：当代综述与分子图谱
Int J Mol Sci. 2023 Dec 12;24(24):17383. doi: 10.3390/ijms242417383.
9
Fibrosis and bone marrow: understanding causation and pathobiology.纤维化与骨髓：病因与病理生物学的认识。
J Transl Med. 2023 Oct 9;21(1):703. doi: 10.1186/s12967-023-04393-z.
10
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms.IL-13/IL-4 信号通路促进骨髓增殖性肿瘤的纤维化进展。
Blood. 2022 Dec 29;140(26):2805-2817. doi: 10.1182/blood.2022017326.
本文引用的文献
1
Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.造血细胞中 CXCL4 表达增加将炎症与 MPN 骨髓纤维化的进展联系起来。
Blood. 2020 Oct 29;136(18):2051-2064. doi: 10.1182/blood.2019004095.
2
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.血小板生成素对于 JAK2V617F 转基因小鼠模型真性红细胞增多症的完全表型表达是必需的。
PLoS One. 2020 Jun 1;15(6):e0232801. doi: 10.1371/journal.pone.0232801. eCollection 2020.
3
Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets.单细胞分析揭示骨髓纤维化中巨核细胞偏向性造血并鉴定突变克隆特异性靶点。
Mol Cell. 2020 May 7;78(3):477-492.e8. doi: 10.1016/j.molcel.2020.04.008.
4
Single-cell analysis based dissection of clonality in myelofibrosis.单细胞分析解析骨髓纤维化中的克隆性。
Nat Commun. 2020 Jan 7;11(1):73. doi: 10.1038/s41467-019-13892-x.
5
Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis.与 PMF 患者向骨髓纤维化快速进展相关的年龄相关克隆性造血突变。
Leukemia. 2020 May;34(5):1364-1372. doi: 10.1038/s41375-019-0668-5. Epub 2019 Nov 27.
6
Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.阐明骨髓增殖性肿瘤分子发病机制的进展及其在治疗决策中的应用。
Int J Hematol. 2020 Feb;111(2):182-191. doi: 10.1007/s12185-019-02778-9. Epub 2019 Nov 18.
7
Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.描述了一种 JAK2V617F MPN 的敲入小鼠模型，该模型源自少数突变造血干细胞。
Blood. 2019 Dec 26;134(26):2383-2387. doi: 10.1182/blood.2019001163.
8
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.巨核细胞中突变钙网蛋白与 SOCE 的缺陷相互作用与骨髓增殖性肿瘤。
Blood. 2020 Jan 9;135(2):133-144. doi: 10.1182/blood.2019001103.
9
Mutant calreticulin in myeloproliferative neoplasms.骨髓增殖性肿瘤中的突变钙网织蛋白。
Blood. 2019 Dec 19;134(25):2242-2248. doi: 10.1182/blood.2019000622.
10
Myelofibrosis in 2019: moving beyond JAK2 inhibition.2019 年骨髓纤维化：超越 JAK2 抑制。
Blood Cancer J. 2019 Sep 11;9(9):74. doi: 10.1038/s41408-019-0236-2.
Zotero 插件